Objective To investigating the value of bifidobacteria triplex(BDT)with second-generation sequencing technology(NGS)in the adjuvant treatment of patients with severe pneumonia.Methods A total of 100 patients with severe pneumonia were selected from December 2020 to December 2022,and were divided into a control group and an experimental group of 50 cases each group according to the statistical randomization method.The control group was treated with empirical anti-infective therapy,while the experimental group was treated with NGS for the pathogenetic analysis of alveolar lavage fluid,and the anti-infective therapy was tailored to the detected pathogens,and BDT was added to assist the treatment.The efficacy of the two groups was compared;the changes of intestinal probiotics(Bifidobacterium bifidum,Lactobacillus acidophilus,Enterococcus faecalis),inflammatory factors[interleukin-6(IL-6),calcitoninogen(PCT),C-reactive protein(CRP)]and lung infections in the two groups were compared;the positive rate of lung pathogens detection in the two groups after treatment was compared.Results After treatment,the total effective rate of treatment and the counts of Bifidobacterium bifidum,Lactobacillus acidophilus,and Enterococcus faecalis in the experimental group were significantly higher than those in the control group(P<0.05),and the scores of pulmonary infections,the positive rate of detection of pulmonary pathogens,and IL-6,PCT,and CRP were significantly lower than those in the control group(P<0.05).Conclusion NGS helps to guide the anti-infective treatment of patients with severe pneumonia,and can clarify the clinical effect of BDT-assisted treatment of severe pneumonia that can improve their intestinal flora and reduce their lung infections.
维普
万方数据
